BSE - Free Realtime Quote INR

Shukra Pharmaceuticals Limited (SHUKRAPHAR.BO)

14.06
0.00
(0.00%)
As of June 9 at 3:15:01 PM GMT+5:30. Market Open.
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Total Revenue
325,873
325,873
745,729
588,336
204,860
Cost of Revenue
81,117
81,117
444,864
453,166
103,458
Gross Profit
244,756
244,756
300,865
135,170
101,402
Operating Expense
147,507
147,507
127,334
99,911
89,168
Operating Income
97,249
97,249
173,531
35,259
12,234
Net Non Operating Interest Income Expense
-5,949
-5,949
-2,850
-2,169
-2,552
Pretax Income
133,366
133,366
198,833
44,417
10,180
Tax Provision
37,614
37,614
13,461
432
2,673
Net Income Common Stockholders
95,751
95,751
185,372
44,065
7,507
Diluted NI Available to Com Stockholders
95,751
95,751
185,372
44,065
7,507
Basic EPS
0.22
--
16.93
0.66
0.02
Diluted EPS
0.22
--
16.93
6.55
0.25
Basic Average Shares
435,231.82
--
10,946.99
67,259.68
30,095.36
Diluted Average Shares
435,231.82
--
10,946.99
6,725.97
300,953.60
Rent Expense Supplemental
--
--
4,867
5,449
7,097
Total Expenses
228,624
228,624
572,198
553,077
192,626
Net Income from Continuing & Discontinued Operation
95,751
95,751
185,372
44,065
7,507
Normalized Income
95,751
95,751
183,046.84
39,745.42
7,269.55
Interest Income
--
--
5,591
639
314
Interest Expense
5,949
5,949
2,850
2,556
2,813
Net Interest Income
-5,949
-5,949
2,741
-2,169
-2,552
EBIT
139,315
139,315
201,596
46,973
12,993
EBITDA
169,364
169,364
222,098
65,348
29,614
Reconciled Cost of Revenue
81,117
81,117
444,864
453,166
103,458
Reconciled Depreciation
30,049
30,049
20,502
18,375
16,621
Net Income from Continuing Operation Net Minority Interest
95,751
95,751
185,372
44,065
7,507
Total Unusual Items Excluding Goodwill
0
0
0
4,362
322
Total Unusual Items
0
0
0
4,362
322
Normalized EBITDA
169,364
169,364
222,185
60,986
29,292
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
42.42
84.55
3/31/2022 - 2/23/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

APLLTD.NS Alembic Pharmaceuticals Limited
993.60
+0.38%
 
AKUMS.NS AKUMS DRUGS AND PHARMA L
566.50
-0.32%
 
GLAND.NS Gland Pharma Limited
1,650.00
+0.10%
 
EMCURE.NS EMCURE PHARMACEUTICALS L
1,340.30
+1.09%
 
MANKIND.NS Mankind Pharma Limited
2,362.20
+0.23%
 
ZYDUSLIFE.NS Zydus Lifesciences Limited
975.50
+0.19%
 
NATCOPHARM.NS NATCO Pharma Limited
860.00
-0.36%